Toripalimab: a promising immunotherapeutic advancement in the management of nasopharyngeal carcinoma

This is the authors' abstract. We don't add key points for this paper.

Nasopharyngeal carcinoma (NPC) poses a formidable challenge globally, particularly in regions with high Epstein-Barr virus (EBV) prevalence such as Southern China and Southeast Asia. This malignancy is primarily managed through radiotherapy, with recent advances incorporating induction chemotherapy and immunotherapy showing promise in improving treatment outcomes. Toripalimab, a programmed death receptor-1 (PD-1) blocking antibody, has emerged as a significant therapeutic option, demonstrating efficacy in both monotherapy and combination regimens in clinical trials such as POLARIS-02 and JUPITER-02. However, challenges including immune-related adverse events warrant careful consideration. This article focuses on toripalimab exploring its characteristics, dosage, mechanism of action, and potential benefits in the management of NPC. It aims to provide valuable insights into this treatment option, helping people better understand the potential benefits of toripalimab in managing this rare condition.